New resource on health coverage, Highlights hurdles patients may face accessing needed medicines

New resource on health coverage, Highlights hurdles patients may face accessing needed medicines

Washington, D.C. (October 14, 2014) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched Access Better, a new website designed to educate consumers about the ABCs of health coverage and access to prescription medicines.

The new site introduces important resources to help people better understand how health insurance works and what to expect from their coverage, including a series of white board videos explaining basic insurance terms like deductibles, copays and coinsurance, and how formularies and tiers work.

Subscribe ButtonWhile health insurers apply a range of tools to try to manage health care costs, in some cases the tools put a burden on patients and their providers. A new video featured on the site walks through these possible hurdles and the resources at may help patients overcome them.

"We know health coverage can be confusing and overwhelming – particularly for those purchasing it for the first time – so we wanted to create a simple, straightforward resource to help demystify the process and equip patients to make coverage decisions that are right for them," said PhRMA President and CEO John J. Castellani. "Our primary goal is to ensure patients have access to the health treatments and services they need."

The site also features an interactive glossary of health care terms, news updates, research and primers on coverage basics helping consumers better understand this complex piece of the health care system.

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $550 billion in the search for new treatments and cures, including an estimated $51.1 billion in 2013 alone.

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.